Biotech

All Articles

Actinogen's cortisol blocker neglects period 2 anxiety research study

.Actinogen Medical's cortisol blocker has actually missed out on the major endpoint of a phase 2 res...

Bivictrix makes a decision going personal only method to take ADC right into center

.Antibody-drug conjugates (ADCs) have gone to the center of several a billion-dollar biobuck licensi...

TPG tops up funds to $580M for financial investments around life scientific researches

.Asset supervisor TPG, which has actually assisted biotechs like Sionna Therapeutics as well as Sant...

Merck ceases phase 3 TIGIT trial in bronchi cancer for impossibility

.Merck &amp Co.'s TIGIT system has experienced yet another obstacle. Months after shuttering a phase...

After a tough year, Exscientia folds into Recursion

.After a year described through pipeline hairstyles, the variation of its own CEO and discharges, Ex...

Cullinan, after $25M deal, return bispecific to Port

.Cullinan Rehab was actually impressed sufficient with Port BioMed's bispecific invulnerable reactor...

A nearer examine Strong Biotech's Fierce 15

.Within this full week's episode of "The Top Line," our team are actually diving in to Brutal Biotec...

Lilly deals with stage 2 failing of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's gathering celebrating the commendation of Alz...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of substantial leadership hirings, shootings...

Lykos will definitely ask FDA to reevaluate its own choice complying with being rejected of MDMA therapy for post-traumatic stress disorder

.Following a bad presenting for Lykos Rehabs' MDMA applicant for trauma at a latest FDA advising com...